Takeda, XOMA ink new royalty agreement; amend existing deal
Source: SeekingAlpha
2025-12-30 08:14:57 ET
More on Takeda Pharmaceutical, XOMA
- Takeda: Lack Of Realistic Upside In Japanese Pharma
- Takeda Pharmaceutical Company Limited (TAK) Q2 FY2025 Earnings Call Transcript
- Takeda Pharmaceutical Company Limited FY2025 Q2 - Results - Earnings Call Presentation
- Takeda posts late-stage trial win for oral plaque psoriasis therapy
- XOMA Royalty to acquire Generation Bio
Read the full article on Seeking Alpha
For further details see:
Takeda, XOMA ink new royalty agreement; amend existing deal
Mirum Pharmaceuticals Inc.
NASDAQ: MIRM
MIRM Trading
2.47% G/L:
$92.483 Last:
352,193 Volume:
$90.76 Open:
MIRM Latest News
March 16, 2026 08:00:00 am
Mirum Pharmaceuticals Completes Enrollment in Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Additional Rare Cholestatic Liver Diseases
March 05, 2026 08:00:00 am
Mirum Pharmaceuticals Provides AZURE Clinical Program Update for brelovitug in Chronic Hepatitis Delta Virus
MIRM Stock Data
$5,184,583,745
44,013,457
0.43%
119
N/A
Biotechnology & Life Sciences
Healthcare
US
Foster City
